Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2017 Mar;13(7):615-624.
doi: 10.2217/fon-2016-0434. Epub 2016 Nov 2.

Capecitabine and Temozolomide in Grade 1/2 Neuroendocrine Tumors: A Spanish Multicenter Experience

Affiliations
Multicenter Study

Capecitabine and Temozolomide in Grade 1/2 Neuroendocrine Tumors: A Spanish Multicenter Experience

Guillermo Crespo et al. Future Oncol. .

Abstract

Background & methods: Capecitabine and temozolomide chemotherapy was used in 65 patients with grade 1/2 neuroendocrine tumors (NETs). 46 patients (70.8%) had pancreatic NETs (pNETs).

Results: Response rate was 47.7%, with two complete responses (3.1%), 29 partial responses (44.6%) and 27 patients (41.5%) achieved stable disease. Median progression-free survival was 16.1 months (95% CI: 10.7-21.6) and overall survival was 38.3 months (95% CI: 24.6-51.9). Differences in progression-free survival and overall survival between pNETs and non-pNETs were not found. Nine (13.8%) patients experienced grade 3/4 toxicities, mainly thrombocytopenia (10.8%) and neutropenia (7.7%).

Conclusion: This is the largest reported series of NETs treated with capecitabine and temozolomide in daily practice and shows that this combination is a promising treatment option for both grade 1/2 pNETs and non-pNETs.

Keywords: capecitabine; carcinoids; neuroendocrine tumors; pancreatic neuroendocrine tumors; retrospective study; temozolomide.

Similar articles

See all similar articles

Cited by 10 articles

See all "Cited by" articles

Publication types

LinkOut - more resources

Feedback